NeoGenomics (NASDAQ:NEO) 주식

NEOGENOMICS INC

NeoGenomics

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Tokyo,,Japan,-,November,21,,2018:,A,Shake,Shack,Fast

News

Movers

ACHC

CVLT

CWAN

DRVN

FTDR

HWKN

IDCC

LUMN

RGEN

SHAK

ZETA

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 루멘 테크놀러지스(NYSE:LUMN)의 주가는 65.95% 상승했다. 이 회사는 데이터 센터의 AI 수요를 지원하기 위해 코닝과 차세대 광섬유 케이블 공급 계약을 체결했다.

쉐이크쉑와 루멘 테크는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (7월 28일-8월 3일)

NeoGenomics Inc

Neo - United States Dollar

Neogen Corp

NeoJapan Inc

NEOMEDIA TECHS INC by NeoMedia Technologies, Inc.

NeoMedia Technologies Inc

Neonode Inc

Neon - United States Dollar

NEO - TrueUSD

NeoVolta Inc

<h3>Companies Reporting Before The Bell</h3>
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $120.47 million. 
• Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $28.07 million. 
• Gogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $214.44 million. 
• Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $21.60 million. 
• ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is projected to report quarterly loss at $0.06 per share on revenue of $180.69 million. 
• TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $650.27 million. 
• EchoStar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) is projected to report quarterly loss at $0.80 per share on revenue of $3.87 billion. 
• Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) is projected to report quarterly loss at $0.05 per share on revenue of $285.18 million. 
• Essent Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESNT#NYSE">ESNT</a>) is projected to report quarterly earnings at $1.65 per share on revenue of $310.79 million. 
• Veren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRN#NYSE">VRN</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $719.90 million. 
• TXNM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXNM#NYSE">TXNM</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $432.72 million. 
• Algonquin Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $652.63 million. 
• Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) is expected to report quarterly earnings at $0.59 per share on revenue of $261.77 million. 
• Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $57.10 million. 
• American Strategic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) is projected to report earnings for its first quarter. 
• Plains All American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $14.00 billion. 
• Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) is expected to report quarterly earnings at $0.95 per share on revenue of $10.31 billion. 
• Creative Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) is estimated to report earnings for its first quarter. 
• uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) is estimated to report quarterly loss at $0.96 per share on revenue of $6.10 million. 
• Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) is projected to report earnings for its first quarter. 
• Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) is likely to report quarterly loss at $0.01 per share on revenue of $23.68 million. 
• Ultralife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $54.50 million. 
• TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) is projected to report quarterly loss at $0.06 per share on revenue of $47.69 million. 
• NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is likely to report quarterly loss at $0.14 per share on revenue of $1.87 million. 
• PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) is expected to report quarterly loss at $0.04 per share on revenue of $105.16 million. 
• InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $1.45 million. 
• Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) is projected to report quarterly loss at $0.05 per share on revenue of $29.22 million. 
• Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) is projected to report quarterly loss at $0.52 per share on revenue of $918.50 million. 
• Koppers Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOP#NYSE">KOP</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $488.00 million. 
• Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) is likely to report quarterly loss at $0.27 per share on revenue of $6.63 million. 
• Associated Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AC#NYSE">AC</a>) is estimated to report quarterly loss at $0.47 per share on revenue of $5.33 billion. 
• Federal Agricultural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGM#NYSE">AGM</a>) is estimated to report earnings for its first quarter. 
• Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) is estimated to report quarterly loss at $0.90 per share on revenue of $10.73 million. 
• First Trust Switzerland AlphaDEX Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSZ#NASDAQ">FSZ</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $171.64 million. 
• Sylvamo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLVM#NYSE">SLVM</a>) is likely to report quarterly earnings at $0.69 per share on revenue of $817.58 million. 
• Strawberry Fields REIT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STRW#AMEX">STRW</a>) is projected to report earnings for its first quarter. 
• AMC Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) is estimated to report quarterly earnings at $0.81 per share on revenue of $567.23 million. 
• Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) is likely to report quarterly loss at $0.17 per share on revenue of $586.15 million. 
• Construction Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>) is likely to report quarterly loss at $0.06 per share on revenue of $559.61 million. 
• Starwood Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $468.00 million. 
• BKV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKV#NYSE">BKV</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $208.66 million. 
• 1stdibs.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) is expected to report quarterly loss at $0.13 per share on revenue of $22.28 million. 
• Plains GP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NASDAQ">PAGP</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $12.97 billion. 
<h3>Companies Reporting After The Bell</h3>
• Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) is estimated to report earnings for its first quarter. 
• ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) is projected to report earnings for its first quarter. 
• Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) is expected to report earnings for its first quarter. 
• Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is projected to report earnings for its first quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

AMCX

ANIK

ANIP

CLMT

CMCT

DCBO

DIBS

EMBC

ESNT

GOGO

INUV

KYMR

LOGC

MSGM

NSPR

OCGN

ORLA

PAGP

QURE

ROAD

RPID

SATS

SLVM

STRW

STWD

TIXT

TXNM

ULBI

WULF

Earnings Scheduled For May 9, 2025

NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that NeoGenomics will report an earnings per share (EPS) of $-0.01. 
The market awaits NeoGenomics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 2.54% increase in the share price on the subsequent day.
Here's a look at NeoGenomics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.01</td>
<td>0.03</td>
<td>0.01</td>
<td>0</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0</td>
<td>0.04</td>
<td>0.05</td>
<td>0.03</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>4.0%</td>
<td>18.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746716500_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of NeoGenomics were trading at $8.0 as of May 07. Over the last 52-week period, shares are down 49.08%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Insights Shared by Analysts on NeoGenomics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding NeoGenomics.
The consensus rating for NeoGenomics is Buy, based on 9 analyst ratings. With an average one-year price target of $12.94, there's a potential 61.75% upside.
<h3>Comparing Ratings with Competitors</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of OPKO Health, Pennant Gr and Pediatrix Medical Group, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for OPKO Health, with an average 1-year price target of $2.68, suggesting a potential 66.5% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Pennant Gr, with an average 1-year price target of $34.67, suggesting a potential 333.38% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Pediatrix Medical Group, with an average 1-year price target of $18.12, suggesting a potential 126.5% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
In the peer analysis summary, key metrics for OPKO Health, Pennant Gr and Pediatrix Medical Group are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeoGenomics</td>
<td>Buy</td>
<td>7.55%</td>
<td>$73.25M</td>
<td>-2.90%</td>
</tr>
<tr>
<td>OPKO Health</td>
<td>Buy</td>
<td>-13.66%</td>
<td>$42.62M</td>
<td>-5.05%</td>
</tr>
<tr>
<td>Pennant Gr</td>
<td>Outperform</td>
<td>29.42%</td>
<td>$25.00M</td>
<td>2.49%</td>
</tr>
<tr>
<td>Pediatrix Medical Group</td>
<td>Neutral</td>
<td>-7.42%</td>
<td>$102.64M</td>
<td>2.67%</td>
</tr>
</tbody>
</table>

Key Takeaway:
NeoGenomics ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit and Return on Equity.
<h3>All You Need to Know About NeoGenomics</h3>
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
<h3>Understanding the Numbers: NeoGenomics's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, NeoGenomics showcased positive performance, achieving a revenue growth rate of 7.55% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: NeoGenomics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -15.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.9%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): NeoGenomics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.6%, the company may face hurdles in achieving optimal financial performance.
Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average at 0.68, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/NEO/earnings">To track all earnings releases for NeoGenomics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at NeoGenomics's Upcoming Earnings Report

In the last three months, 9 analysts have published ratings on NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated NeoGenomics and provided 12-month price targets. The average target is $12.94, accompanied by a high estimate of $18.00 and a low estimate of $8.50. This current average represents a 31.1% decrease from the previous average price target of $18.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1746565266_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of NeoGenomics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$9.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.50</td>
<td>$18.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NeoGenomics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NeoGenomics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NeoGenomics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NEO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NeoGenomics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into NeoGenomics's Background</h2>
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
<h3>Unraveling the Financial Story of NeoGenomics</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: NeoGenomics's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 7.55%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: NeoGenomics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -15.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.9%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.6%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average. With a ratio of 0.68, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing NeoGenomics: Insights From 9 Financial Analysts

Piper Sandler analyst David Westenberg maintains NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Overweight and lowers the price target from $18 to $12.

Price Target

Piper Sandler Maintains Overweight on NeoGenomics, Lowers Price Target to $12

Morgan Stanley analyst Tejas Savant maintains NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Equal-Weight and lowers the price target from $17 to $10.

Morgan Stanley Maintains Equal-Weight on NeoGenomics, Lowers Price Target to $10

Goldman Sachs analyst Matthew Sykes maintains NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Buy and lowers the price target from $15 to $10.

Goldman Sachs Maintains Buy on NeoGenomics, Lowers Price Target to $10

WIIM

NeoGenomics shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $25 to $9.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Tami Zakaria downgraded the rating for PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from Overweight to Neutral and lowered the price target from $105 to $90. PACCAR shares closed at $90.29 on Tuesday. <a href="https://www.benzinga.com/quote/PCAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Puneet Souda downgraded the rating for NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) from Outperform to Market Perform and cut the price target from $25 to $9. NeoGenomics shares closed at $6.58 on Tuesday. <a href="https://www.benzinga.com/quote/NEO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Ike Boruchow downgraded the rating for NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Overweight to Equal-Weight and cut the price target from $75 to $55. Nike shares closed at $57.54 on Tuesday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Puneet Souda downgraded Quanterix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) from Outperform to Market Perform and slashed the price target from $12 to $8. Quanterix shares closed at $6.05 on Tuesday. <a href="https://www.benzinga.com/quote/QTRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Ike Boruchow downgraded The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) from Overweight to Equal-Weight and lowered the price target from $30 to $24. Gap shares closed at $21.76 on Tuesday.  <a href="https://www.benzinga.com/quote/GAP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Nike stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30075139/image-233-1024x587.png" alt="" class="wp-image-894704" style="width:520px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30075139/image-233-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30075139/image-233-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30075139/image-233-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30075139/image-233.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

PCAR

QTRX

This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler raised Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) price target from $383 to $384. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Visa shares closed at $341.52 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/V/analyst-ratings">view this stock</a>.</li>
<li>TD Securities cut the price target for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from $102 to $90. TD Securities analyst Agnes Lim maintained a Buy rating. Starbucks shares closed at $84.85 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">view this stock</a>.</li>
<li>Needham cut AtriCure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) price target from $51 to $44. Needham analyst Mike Matson maintained a Buy rating. AtriCure shares closed at $34.65 on Tuesday. See how other <a href="https://www.benzinga.com/quote/ATRC/analyst-ratings">analysts view this stock</a>.</li>
<li>DA Davidson cut the price target for Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from $170 to $155. DA Davidson analyst Tom White upgraded the stock from Neutral to Buy. Airbnb shares closed at $125.49 on Tuesday. <a href="https://www.benzinga.com/quote/ABNB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from $105 to $90. JP Morgan analyst Tami Zakaria downgraded the stock from Overweight to Neutral. PACCAR shares closed at $90.29 on Tuesday. <a href="https://www.benzinga.com/quote/PCAR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners lowered NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) price target from $25 to $9. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. NeoGenomics shares settled at $6.58 on Tuesday. <a href="https://www.benzinga.com/quote/NEO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners cut Quanterix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) price target from $12 to $8. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. Quanterix shares closed at $6.05 on Tuesday. <a href="https://www.benzinga.com/quote/QTRX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) price target from $15 to $8. HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating. Zynex shares closed at $2.23 on Tuesday.  <a href="https://www.benzinga.com/quote/ZYXI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup lowered the price target for Warby Parker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) from $23 to $19. Citigroup analyst Paul Lejuez upgraded the stock from Sell to Neutral. Warby Parker shares settled at $15.80 on Tuesday. <a href="https://www.benzinga.com/quote/WRBY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank increased T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) price target from $275 to $277.5. Scotiabank analyst Maher Yaghi upgraded the stock from Sector Perform to Sector Outperform. T-Mobile US shares closed at $241.59 on Tuesday. <a href="https://www.benzinga.com/quote/TMUS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying Visa stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-1024x593.png" alt="" class="wp-image-894667" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

ABNB

ATRC

SBUX

TMUS

WRBY

ZYXI

Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

Leerink Partners analyst Puneet Souda downgrades NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) from Outperform to Market Perform and lowers the price target from $25 to $9.

Leerink Partners Downgrades NeoGenomics to Market Perform, Lowers Price Target to $9

Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Buy and lowers the price target from $18 to $8.5.

Needham Maintains Buy on NeoGenomics, Lowers Price Target to $8.5

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares rose 50.4% to $0.02 during Tuesday's regular session. </li>
<li>Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) stock rose 39.13% to $4.97. The market value of their outstanding shares is at $30.2 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares increased by 33.48% to $5.74. The market value of their outstanding shares is at $3.0 million. </li>
<li>LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) shares moved upwards by 32.78% to $8.1. The market value of their outstanding shares is at $361.1 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 27.14% to $1.33. The market value of their outstanding shares is at $13.1 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) stock rose 26.12% to $35.92. The company's market cap stands at $8.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 71.0% to $0.02 during Tuesday's regular session. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares decreased by 34.63% to $9.25. The company's market cap stands at $438.3 million. </li>
<li>NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) stock declined by 31.9% to $6.79. The market value of their outstanding shares is at $872.2 million. The company's, Q1 earnings came out today. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock decreased by 25.2% to $4.84. The company's market cap stands at $2.9 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock declined by 23.37% to $4.56. The company's market cap stands at $69.4 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock fell 15.99% to $0.3. The company's market cap stands at $9.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IBIO

KALA

LFMD

LGMK

NDRA

PTPI

RLMD

TIVC

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 250 points on Tuesday.
The Dow traded up 0.70% to 40,507.41 while the NASDAQ rose 0.30% to 17,417.49. The S&amp;P 500 also rose, gaining, 0.37% to 5,548.98.
Check This Out: <a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a>
Leading and Lagging Sectors Materials shares jumped by 0.6% on Monday.
In trading on Monday, consumer discretionary fell by 0.5%.
Top Headline
Shares of Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) gained around 3% on Tuesday after the company reported better-than-expected earnings for its first quarter.
Pfizer posted quarterly earnings of 92 cents per share, beating market estimates of 67 cents per share. The company's quarterly sales came in at $13.71 billion, missing expectations of $13.95 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares shot up 18% to $33.69 after the company announced a collaboration with Novo Nordisk to offer a bundled package of all dose strengths of Wegovy on its platform.</li>
<li>Shares of Leggett &amp; Platt, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>)got a boost, surging 24% to $9.02 after the company reported better-than-expected first-quarter EPS results and raised its FY25 EPS guidance.</li>
<li>WW International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares were also up, gaining 86% to $0.7723 after the company announced a pharmacy integration with Eli Lilly&#8217;s LillyDirect pharmacy provider, Gifthealth.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) shares dropped 22% to $7.75 following a first-quarter revenue miss.</li>
<li>Shares of Piedmont Office Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDM#NYSE">PDM</a>) were down 17% to $5.66 after the company posted first-quarter results.</li>
<li>Insperity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) was down, falling 15% to $66.88 following weaker-than-expected quarterly earnings.</li>
</ul>
Commodities In commodity news, oil traded down 2.4% to $60.54 while gold traded down 0.6% at $3,327.80.
Silver traded up 1.6% to $33.545 on Tuesday, while copper fell 0.2% to $4.8780.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.21%, Germany's DAX 40 gained 0.55% and France's CAC 40 fell 0.28%. Spain's IBEX 35 Index fell 0.80%, while London's FTSE 100 rose 0.28%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with China's Shanghai Composite falling 0.05%, Hong Kong's Hang Seng Index gaining 0.16% and India's BSE Sensex gaining 0.09%.
Economics
<ul>
<li>The number of job openings in the U.S. declined by 288,000 to 7.192 million in March, compared to market estimates of 7.48 million.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 4.5% year-over-year in February.</li>
<li>The FHFA house price index increased by 0.1% in February versus a revised 0.3% rise in January.</li>
<li>U.S. wholesale inventories climbed 0.5% month-over-month to $908 billion during March.</li>
<li>The U.S. trade deficit in goods increased to $162 billion in March compared to market estimates of a $146 billion gap. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45065334/amazon-com-to-253-here-are-10-top-analyst-forecasts-for-tuesday">Amazon.com To $253? Here Are 10 Top Analyst Forecasts For Tuesday</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings

NeoGenomics shares are trading lower following a Q1 revenue miss.

Guidance

NeoGenomics Raises FY2025 Adj EPS Guidance from $0.15-$0.19 to $0.16-$0.20 vs $0.18 Est

NeoGenomics Raises FY2025 Sales Guidance from $735.00M-$745.00M to $747.00M-$759.00M vs $739.39M Est

Earnings Misses

NeoGenomics Q1 Sales $168.03M Miss $170.96M Estimate

ACGL

AEYE

AMSF

APAM

ARCB

ARCC

ASTE

ASTL

BBIO

BBVA

BGFV

BKNG

BRSP

CECO

CHCT

CLVT

CSGP

DHIL

ENSG

ENVA

ESRT

ETWO

EXLS

FELE

FFIC

FIBK

FICO

FOUR

FRSH

FRST

FSLR

FYBR

HLMN

HOUS

HRZN

HSBC

HURN

ILPT

INCY

INTZ

JAKK

JBGS

JBLU

KNSA

LFUS

LGIH

Laboratory Corporation Of America Holdings

LOGI

LXFR

Earnings Scheduled For April 29, 2025

NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect NeoGenomics to report an earnings per share (EPS) of $-0.01.
The market awaits NeoGenomics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.01 in the last quarter, leading to a 2.54% increase in the share price on the following day.
Here's a look at NeoGenomics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.03</td>
<td>0.01</td>
<td>0</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.05</td>
<td>0.03</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>4.0%</td>
<td>18.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866952_0.png" alt="eps graph" />
<h3>Market Performance of NeoGenomics's Stock</h3>
Shares of NeoGenomics were trading at $10.27 as of April 25. Over the last 52-week period, shares are down 29.74%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Observations about NeoGenomics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding NeoGenomics.
The consensus rating for NeoGenomics is Buy, derived from 5 analyst ratings. An average one-year price target of $17.0 implies a potential 65.53% upside.
<h3>Comparing Ratings with Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Astrana Health, OPKO Health and Pediatrix Medical Group, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Astrana Health, with an average 1-year price target of $47.4, suggesting a potential 361.54% upside.</li>
<li>Analysts currently favor an Buy trajectory for OPKO Health, with an average 1-year price target of $2.75, suggesting a potential 73.22% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Pediatrix Medical Group, with an average 1-year price target of $17.5, suggesting a potential 70.4% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary outlines pivotal metrics for Astrana Health, OPKO Health and Pediatrix Medical Group, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeoGenomics</td>
<td>Buy</td>
<td>10.57%</td>
<td>$77.26M</td>
<td>-1.69%</td>
</tr>
<tr>
<td>Astrana Health</td>
<td>Buy</td>
<td>88.43%</td>
<td>$50.48M</td>
<td>-0.98%</td>
</tr>
<tr>
<td>OPKO Health</td>
<td>Buy</td>
<td>0.95%</td>
<td>$84.66M</td>
<td>1.01%</td>
</tr>
<tr>
<td>Pediatrix Medical Group</td>
<td>Neutral</td>
<td>1.19%</td>
<td>$128.53M</td>
<td>4.07%</td>
</tr>
</tbody>
</table>

Key Takeaway:
NeoGenomics ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. For Return on Equity, NeoGenomics is at the bottom.
<h3>About NeoGenomics</h3>
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
<h3>A Deep Dive into NeoGenomics's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining NeoGenomics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.57% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: NeoGenomics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -8.91%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): NeoGenomics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.93%, the company may face hurdles in achieving optimal financial returns.
Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average. With a ratio of 0.67, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/NEO/earnings">To track all earnings releases for NeoGenomics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: NeoGenomics's Quarterly Earnings

NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), a leading provider of oncology testing services, today announced the analytical validation of its PanTracer LBx&#x2122; assay, a next-generation sequencing (NGS) liquid biopsy panel designed for comprehensive pan-solid tumor profiling. The validation study, along with five additional abstracts, will be presented at the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aacr.org%2Fmeeting%2Faacr-annual-meeting-2025%2F&amp;esheet=54241323&amp;newsitemid=20250422684655&amp;lan=en-US&amp;anchor=American+Association+for+Cancer+Research%26%23174%3B+%28AACR%29+Annual+Meeting+2025&amp;index=1&amp;md5=538c83eb0e4bfde5252c7ea7eb2eb17d">American Association for Cancer Research&#xAE; (AACR) Annual Meeting 2025</a> in Chicago, April 25–30.
PanTracer LBx is a blood-based test that analyzes circulating tumor DNA to identify key genomic alterations in patients with advanced-stage solid tumors. It is designed to support treatment decisions when tumor tissue is unavailable or insufficient—a common challenge in oncology care. In the validation study, PanTracer LBx demonstrated high performance in identifying key biomarkers—including MSI (microsatellite instability) and TMB (tumor mutational burden)—across multiple cancer types, reinforcing its potential to guide therapy selection and expand access to precision oncology. The poster, "<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.abstractsonline.com%2Fpp8%2F%23%21%2F20273%2Fpresentation%2F9244&amp;esheet=54241323&amp;newsitemid=20250422684655&amp;lan=en-US&amp;anchor=Analytical+validation+of+PanTracer+LBx+performance%2C+a+comprehensive+pan-solid+tumor+liquid+biopsy+assay&amp;index=2&amp;md5=a684bfb8418de263ab1c83d683307b44">Analytical validation of PanTracer LBx performance, a comprehensive pan-solid tumor liquid biopsy assay</a>," will be presented on Tuesday, April 29, from 9 AM - 12 PM CT, Section 10, Poster 27.
NeoGenomics has also launched an Evaluation Assessment Program for PanTracer LBx, allowing select physicians to use the assay ahead of full commercial availability. The program is intended to identify opportunities to streamline logistics, reporting, and customer support.

NeoGenomics Validates PanTracer LBx, A Blood Test for Comprehensive Tumor Profiling

Press Releases

NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

NeoGenomics Completes Acquisition of Pathline

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

NeoGenomics Reports First Quarter 2025 Results

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

Comments

NeoGenomics

뉴스

파트너 / 기고자

벤징가 글로벌